SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biopharmaceutical company using allosteric regulation to create conditionally active and less toxic medicines, today announced a $93 million Series A ...
SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional activation of biologics to create highly active and less toxic medicines, ...
Good Therapeutics spinout Bonum Therapeutics has raked in $93 million to develop a new class of conditionally active therapies, with backing from Roche's venture arm. Bonum, which means “good” in ...
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025 Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation ...
Seattle-based Bonum Therapeutics designs therapies that can be administered systemically for targeted activation in the body. (Good Therapeutics Graphic) Seattle biotech startup Bonum Therapeutics ...
John Mulligan, PhD, founder and CEO at Bonum Therapeutics. Bonum Therapeutics, a biopharmaceutical startup that uses allosteric control to develop conditionally active and less toxic medications, has ...
Trxade Group's telehealth subsidiary, Bonum Health is entering a new partnership meant to boost telemedicine access for Kinney Drugs patients and ProAct members. The partnership with pharmaceutical ...
The profit for Bonum Bank Plc, belonging to POP Bank Group, for the financial year increased to EUR 1,046 thousand (EUR 712 thousand) and balance sheet grew to EUR 1,037,914 thousand (EUR 1,006,480 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results